effect overlay
activetrials
Stroke

Colchicine After Stroke to Prevent Event Recurrence (CASPER)
 

HREC: 2022.202
Principal Investigator: Prof Bruce Campbell
Coordinator contact: David Jackson
Funding: Non-Commercial
Stroke

3-Stage, Multi-Centre, EMVision CP2/Gen 1 BrainScanner to Collect Data for Hardware Verification and Software Development for Imaging Acute Stroke from Healthy Participants and Participants Presenting with Stroke Symptoms to the Emergency Department
 

HREC: 2022.303
Principal Investigator: Dr Angela Dos Santos
Coordinator contact: Dr Anna Balabanski
Funding: Commercial
Stroke

Expanding Stroke therapy access, Stroke in patients with Large ishemic core
 

HREC: 2022.322
Principal Investigator: Prof Bruce Campbell
Coordinator contact:
Funding: Non-Commercial
Stroke

A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
 

HREC: 2023.046
Principal Investigator: Prof Bruce Campbell
Coordinator contact: Nicola Parsons
Funding: Commercial

"A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic
stroke or high-risk TIA"
 

HREC: 2023.051
Principal Investigator: Prof Bruce Campbell
Coordinator contact: Laura Fiscchia
Funding: Commercial